Regarding the type of IBD, for UC 101 cases had received anti-TNF, 28 vedolizumab, three ustekinumab and 149 no biological therapy, while for CD 477 had received anti-TNF, 30 vedolizumab, 66 ustekinumab and 665 no biological therapy. This evidence concerns the gene TNF and inflammatory bowel disease.